Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
103.80    0.60 (0.58%)
Bid:
103.80
Ask:
105.00
Spread: 1.20 (1.156%)
Market Cap: £170.17m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Interim Management Statement

12 May 2011 07:00

RNS Number : 4433G
Yule Catto & Co PLC
12 May 2011
 



12 May 2011

 

Yule Catto & Co plc (the "Group") 

 

Interim Management Statement

 

At this afternoon's AGM of Yule Catto & Co plc, the international producer of speciality chemicals, Chairman Peter Wood will make the following statement which also comprises the Group's interim management statement for the period 1 January 2011 to date.

 

The Group's earnings for the first quarter were well ahead of the same period last year excluding any impact of the PolymerLatex acquisition, and the Board's expectations for financial performance for 2011 remain unchanged.

 

Overall demand in Yule Catto's Polymer business was solid. Asian demand was strong through the quarter, whilst Europe firmed after a slow start in the UK. Ongoing very substantial monomer price increases have had to be passed on to customers, resulting in the usual temporary margin compression as the increases are recovered and target unit margins per tonne restored. Consequently, although volumes increased in Polymers and turnover was strongly ahead, operating profit was flat year on year in the first quarter. Whilst Europe lagged the prior year, Asia was ahead, despite, as expected, profits being temporarily constrained by capacity during the quarter. This position will be resolved in the course of the second quarter with the new 15,000 tonne nitrile expansion coming on line and some spare capacity in the acquired PolymerLatex nitrile assets. In April, the existing Yule Catto polymer business performed ahead of prior year.

 

The acquisition of PolymerLatex completed at the end of March as anticipated. Integration planning progressed through the first quarter and is now being implemented. Post acquisition, the synergy potential has been confirmed, and management remain highly confident that at least £20m of synergies will be delivered as disclosed at the time of the acquisition announcement and to the same timetable. Regular updates on progress in delivering these synergies will be provided to investors, with the first update to be delivered with the group's half year results in August. As at the date of this statement, actions taken to date have already delivered synergies with an annual run rate value of approximately £2m.

 

PolymerLatex itself traded comfortably ahead of last year in the first quarter, and this has continued through April. The business benefited from good demand in central Europe for latex and volume growth in its Malaysian nitrile facility. Plans are already being developed for very substantial increases in capacity in Asia for nitrile and SBR latex to be brought on line before the end of 2012.

 

In the Group's other businesses in the first quarter, the Pharma division performed well ahead of what was a very weak result in the same period last year, whilst William Blythe continued to grow profits strongly.

 

Net debt at the end of the quarter stood at £235m reflecting the impact of the acquisition of PolymerLatex, in line with the Group's forecasts at the time of the acquisition announcement.

 

- Ends -

 

ENQUIRIES:

 

Yule Catto & Co plc

Tel: 01279 442791

Adrian Whitfield, Chief Executive

David Blackwood, Group Finance Director

MHP Communications

Tel: 020 3128 8100

Andrew Jaques

John Olsen

Ian Payne

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSLFFLFERILLIL
Date   Source Headline
6th Oct 20238:53 amRNSHolding(s) in Company
5th Oct 20232:40 pmRNSDirector/PDMR Shareholding
5th Oct 202312:27 pmRNSHolding(s) in Company
2nd Oct 20232:22 pmRNSHolding(s) in Company
28th Sep 20237:00 amRNSAdmission of Nil Paid Rights
27th Sep 20237:00 amRNSDespatch of PALs
26th Sep 20237:00 amRNSCapital Reorganisation
25th Sep 20231:58 pmRNSResults of General Meeting
22nd Sep 20233:21 pmRNSAdditional Listing
7th Sep 20233:44 pmRNSPublication of a Prospectus
7th Sep 20237:00 amRNSRights Issue
7th Sep 20237:00 amRNSHalf-year results
18th Jul 20237:00 amRNSPost-close trading update
12th Jul 20233:17 pmRNSAppointment of Non-Executive Director
28th Jun 202312:37 pmRNSDirector/PDMR Shareholding
28th Jun 202312:36 pmRNSDirector/PDMR Shareholding
22nd Jun 202310:20 amRNSDirector/PDMR Shareholding
16th May 20234:00 pmRNSResult of AGM
16th May 20237:00 amRNSAGM trading update
12th May 20231:08 pmRNSDirector/PDMR Shareholding
12th May 20231:06 pmRNSDirector/PDMR Shareholding
13th Apr 202310:02 amRNSHolding(s) in Company
12th Apr 20235:52 pmRNS2022 Annual Financial Report & Notice of 2023 AGM
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
11th Apr 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
29th Mar 20237:00 amRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSFinal Results
21st Mar 20237:00 amRNSRefinancing
28th Feb 20233:33 pmRNSDisposal
31st Jan 20237:00 amRNSPost-close update for the year ended 31 Dec 2022
11th Jan 202311:30 amRNSResult of General Meeting
16th Dec 202212:12 pmRNSPublication of Circular &Notice of General Meeting
13th Dec 20227:00 amRNSProposed Sale of Laminates, Films & Coated Fabrics
8th Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSBoard changes
29th Nov 202211:16 amRNSOutcome of European Commission investigation
1st Nov 20222:53 pmRNSHolding(s) in Company
27th Oct 202210:27 amRNSHolding(s) in Company
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
25th Oct 20227:00 amRNSDirector/PDMR Shareholding
20th Oct 20227:00 amRNSCovenant relaxation to the end of 2023 agreed
13th Oct 20227:00 amRNSHolding(s) in Company
12th Oct 20227:00 amRNSInvestor Seminar
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
6th Oct 20227:00 amRNSDirector/PDMR Shareholding
4th Oct 202210:40 amRNSDirector/PDMR Shareholding
4th Oct 202210:37 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.